Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 130b (miR-130b) is a small, non-coding RNA molecule involved in the post-transcriptional regulation of gene expression, most notably through silencing of target messenger RNAs. It is encoded in humans by the MIR130B gene. miR-130b is upregulated in multiple aggressive cancers including glioma, colorectal cancer, leiomyosarcoma, and others, where it promotes malignant processes such as cell proliferation, migration, invasion, EMT, and angiogenesis, typically via direct inhibition of tumor suppressor genes including PPARγ, TSC1, and PTEN. High levels of miR-130b in tumors or plasma are associated with poor prognosis and increased tumor aggressiveness. Therapeutic targeting of miR-130b with antisense oligonucleotides is under experimental investigation. The functions of miR-130b can be context-dependent, with occasional tumor suppressor roles observed in specific cell types[1][2][3][4].
Antisense inhibition of miR-130b: blocks its oncogenic regulatory effects, restoring tumor suppressor expression[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 130b (miR-130b).